Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Nave Adult Patients with Metastatic Uveal Melanoma

Disease Sites:

Not Available

Staging:

Phase II/III

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Johnson, Douglas

Participating Institutions:

Vanderbilt University

Open Date:

05-30-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTMEL24090

National Clinical Trial ID:

NCT06581406

Related Internal Documents:

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available